“All About Cancer and Targeted Therapy”
Targeted cancer therapies have revolutionized oncology by focusing on specific molecular pathways that drive tumor growth. Unlike traditional chemotherapy, which affects both cancerous and healthy cells, targeted treatments aim to minimize collateral damage, offering improved efficacy and reduced side effects. Current Developments Recent advancements highlight the potential of targeted therapies: Breast Cancer: A combination of inavolisib and palbociclib with fulvestrant has shown to extend overall survival by seven months and delay disease progression by 17.2 months in patients with PIK3CA-mutated, hormone receptor-positive, HER2-negative metastatic breast cancer . Triple-Negative Breast Cancer (TNBC): Gilead’s Trodelvy, combined with Merck’s Keytruda, reduced cancer progression risk by 35% in PD-L1 positive TNBC patients, establishing a potential new first-line treatment standard . BRCA-Mutated Breast Cancer: A novel treatment combining chemotherapy with olap...